Coming December: ASH publishes its late-breaking abstracts. We’ll add the organizations presenting them.

PharmaEssentia at ASH 2026

Dec 12–15, 2026 New Orleans, LA ~30k attendees Website

PharmaEssentia brings 2 presentations to ASH 2026 in New Orleans, and exhibits at Booth 3739. Its program centres on myeloproliferative neoplasms, especially essential thrombocythemia and polycythemia vera. It hosts a session on managing essential thrombocythemia and supports symposia on real-world care.

OrganizationASH 2026 Attendance
PharmaEssentia
Taipei, Taiwan
Biotech
Taiwan-based biopharmaceutical company making biologics for hematology and oncology, including an approved interferon therapy for polycythemia vera.
Booth
Exhibiting at Booth 3739
Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm
Symposium
Fri Dec 11
11:00am–2:00pm
Show Me the Data™: Emerging Evidence and Evolving Clinical Practice in Essential Thrombocythemia and Polycythemia Vera
Newer options for polycythemia vera and essential thrombocythemia, such as ropeginterferon and rusfertide, and what to do when hydroxyurea fails.
Leukemias
Symposium
Fri Dec 11
3:00pm–6:00pm
Cases and Conversations: Applying Emerging Evidence to Real-World Care in Myeloproliferative Neoplasms
Choosing among new myeloproliferative neoplasm drugs, including Janus kinase and telomerase inhibitors, hepcidin mimetics, and calreticulin-targeted antibodies.
Leukemias

Explore the full ASH 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in New Orleans. Leave your work email and we’ll be in touch.

Privacy

Download the full ASH 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at PharmaEssentia

Tell us what you sell and we’ll find the people at PharmaEssentia most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction